Steve Tuplin/LinkedIn
Dec 6, 2025, 11:50
Steve Tuplin on Roche’s Mission at ASH25
Steve Tuplin, VP, Global Disease Area Head – Hematology and ai Oncology at Roche, shared on LinkedIn:
”Next stop: Orlando!
While many head there for the thrill rides, we are heading to ASH25 for a different kind of excitement: the breakthroughs shaping the future of haematology.
We are looking forward to sharing how our broad portfolio is evolving to meet the real-world needs of patients and the healthcare system.
It’s not about magic; it’s about our unwavering commitment to raising the therapeutic bar and delivering innovation that truly matters.
I’m excited to catch up with those of you attending.
Let me know—what is top of your list for this year?”
All from ASH25 featured in Hemostasis Today.
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria